Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PREDIX HER2 - Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer. Part of a Platform of Translational Phase II Trials Based on Molecular Subtypes

NCT02568839 is registered in ClinicalTrials.gov with Thomas Hatschek as lead sponsor.

NCT NCT02568839
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02568839 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PREDIX HER2 - Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer. Part of a Platform of Translational Phase II Trials Based on Molecular Subtypes
Lead sponsor
Thomas Hatschek
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
November 30, 2014
Completion date
February 28, 2029
Enrollment
202 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

early-stage breast carcinoma, her-2 positive breast cancer